ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record8 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06922591Study to Evaluate theSafety, Tolerability &Efficacy of TNG462 inCombination in PDAC & NSCLCPatientsTango Therapeutics, Inc.Phase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 23 · ClinicalTrials.gov record · Version of 2026-10-23Version of 2026-10-23CONDITIONSLung NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSINT014996Entry “TNG462”, read by our name rule›Nov 18 · Rule based · BackgroundBackgroundZoldonrasibEntry “RMC-9805”, read by our name ru…›Nov 18 · Rule based · BackgroundBackgroundDaraxonrasibEntry “RMC-6236”, read by our name ru…›Nov 10 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerINT010129Entry “mFOLFIRINOX”, read by our name…›Nov 18 · Rule based · BackgroundBackgroundINT009668Entry “gemcitabine/nab-paclitaxel”, r…›Nov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Daraxonrasib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “RMC-6236”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background · partner
Background · partner · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 23The record itselfClinicalTrials.gov recordVersion of 2026-10-23Record change
Nov 10DaraxonrasibClaude Opus 5.5Background · partnerCurrent
Nov 14Lung NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18INT014996Rule based · role ruleBackgroundCurrent
Nov 18ZoldonrasibRule based · role ruleBackgroundCurrent
Nov 18DaraxonrasibRule based · role ruleBackgroundAgrees
Nov 18INT010129Rule based · role ruleBackgroundCurrent
Nov 18INT009668Rule based · role ruleBackgroundCurrent
As of nowLung NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.